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Abstract
Background: In vivo treatment with growth hormone reduces radiation-associated mortality. The
molecular mechanisms underlying this effect are unknown. It has been described that increased
sensitivity to ionising radiation can be due to defects in machinery involved in detection and/or
repair of DNA double-strand breaks.
Objective: To study the mechanisms involved in growth hormone action on the increased survival in
irradiated cells.
Materials and methods: CHO-4 cells stably expressing the growth hormone receptor were used. A cell
viability assay was carried out to analyse the increase in survival induced by growth hormone in
irradiated cells. To investigate whether the DNA repair mechanism could be implicated in this
effect we performed DNA reactivation assays using pHIV-LUC and pCMV-bgal plasmids as control.
Identical studies were also conducted using the radiomimetic drug, bleomycin.
Results: Growth hormone protects CHO-4 cells from bleomycin- and radiation-induced cell death. In
pHIV-LUC transfected cells, a time-dependent decrease in luciferase activity was observed after
irradiation in the absence of growth hormone. However, cells pretreated with this hormone
maintained reporter activity. When cells were transfected with irradiated pHIV-LUC plasmid, only
the hormone-treated cells recovered the transcriptional activity.
Conclusions: Growth hormone exerts a radioprotective effect in CHO-4 cells stably transfected with the
complementary DNA for the rat growth hormone receptor. The radioprotection is triggered directly by
the hormone and it is also observed with bleomycin. The increased survival in response to radiation
and bleomycin treatment induced by growth hormone correlates with an enhanced ability of the cells
to repair damaged DNA.
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Introduction
The cell nucleus is considered the primary target for the
lethal effects of ionising radiation and the heterologous
DNA double-strand breaks are the most common type
of radiation lesions that lead to mammalian cell death
(1). However, the outcome of this damage is not
necessarily cell death since mammalian cells can
repair radiation-induced DNA breaks proficiently (2).
Radiation-induced damage in DNA and other cellular
components triggers cascades of regulatory events in
eukaryotic cells. These events constitute a complex
network of pathways towards cell cycle checkpoints,
DNA repair and damage tolerance mechanisms,
recombination and programmed cell death (apopto-
sis). Several pieces of evidence suggest that certain
growth factors and cytokines can modify cellular
radiosensitivity. Thus, basic fibroblast growth factor
(bFGF) protects bovine aortic and murine intestinal
endothelial cells against radiation-induced pro-
grammed cell death (3, 4); insulin-like growth factor
(IGF)-I (5), keratinocyte growth factor (6), vascular
endothelial growth factor (VEGF) (7) and acid and
basic FGFs (8) exert protective effects on intestine
from radiation injury; interleukin (IL)-1, IL-11, IL-12
and tumour necrosis factor (TNF)-a are radioprotective
in the murine bone marrow (9, 10, 11). Given before
radiation, IL-1, IL-11 and transforming growth factor
(TGF-b)-increase the number of surviving intestinal
crypts after radiation (12 –14).
Growth hormone (GH) is an anabolic hormone with
pleiotropic effects on growth, differentiation and
metabolism of cells (15), although it does not stimulate
in vitro human tumour growth (15). In general, GH
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initiates its biological actions by interaction with a
specific membrane-bound receptor (15). The GH
receptor is phosphorylated upon ligand stimulation by
physical association with the non-receptor tyrosine
kinase JAK2. JAK kinases are linked to transcriptional
regulation and their activation results in the phos-
phorylation, dimerisation, and nuclear translocation
of latent cytoplasmic STAT transcription factors.
These activated STAT factors bind to their appro-
priate DNA-responsive elements and activate gene
transcription (16).
GH has been clinically used in GH-deficient children
(17) and adults (18), in patients recovering from
surgery (19) and in patients with intestinal diseases
like Crohn’s syndrome (20) and inflammatory bowel
disease (21). GH stimulates muscle protein synthesis,
improves the nitrogen balance and promotes wound
healing in a variety of catabolic states (22, 23). In
addition, GH has been shown to reduce radiation-
associated mortality (24). In this context, it has been
reported that, within the bowel of radiated rats, GH
favours the absorptive process by increasing mucosal
proliferation and villous size (24). This protection
exhibits an increase in intestinal crypt proliferation
and a reduction in apoptosis. The mechanism by
which GH reduces the effect of radiation is unknown.
Here we used an in vitro cell system to further investi-
gate the influence of GH on radiation responses. The
results presented here indicate that GH has a protective
action against radiation and this effect seems to be
mediated by its ability to increase the repair of radiation
damaged DNA.
Materials and methods
Cell lines and plasmids
Chinese hamster ovary (CHO)-4 and human
embryonic kidney (HEK) 293T cells were cultured
in Ham’s F-12 medium or Dulbecco’s modified
Eagle’s medium respectively containing 4.5 g/l glucose
and supplemented with 10% fetal calf serum (FCS)
and 1 mM L-glutamine. pHIV-LUC (25) contains
sequences 2453/+80 from the HIV enhancer linked
to the firefly luciferase gene. PCMV-bgal plasmid
contains the prokaryotic b-galactosidase gene inserted
between the cytomegalovirus promoter (CMV) and the
SV40 splice and polyadenylation signals. SPIGLE1
plasmid containing the GAS sequence from the SPI
2.1 promoter was kindly provided by Dr Ugo Moens (26).
DNA reactivation assays
CHO-4 cells were plated 24 h before transfection at a
density of 3 £ 105 cells/60 mm plate. Cells were trans-
fected with the plasmid pHIV-LUC by the calcium
phosphate method as described (25). Sixteen hours
after transfection cells were fed with low serum
medium (0.5%) and treated with different concen-
trations of recombinant human GH (hGH, Serono,
Madrid, Spain) for a further 4 h. Then, cells were irra-
diated using a telecobaltotherapy unit (60CO27
Model Theratron-80, MDS Nordion, Kanata, Ontario,
Canada). Cell extracts were obtained as described
before (25) at different times after irradiation and
assayed for luciferase activity. Alternatively pHIV-LUC
plasmid was irradiated with different doses and trans-
fected together with pCMV-bgal plasmid as a control,
by the calcium phosphate method. Sixteen hours after
medium was removed, cells were fed with low serum
medium (0.5%) and supplemented when indicated with
different doses of GH. Cells extracts were prepared 48 h
after transfection and assayed for b-galactosidase and
luciferase activity. Fold activation was obtained by nor-
malising luciferase activity to b-galactosidase expression.
Gene expression analysis
Cells were transfected with the indicated plasmids and
harvested at different times after treatment. Protein
extracts were prepared by three consecutive cycles of
freezing and thawing. The total amount of protein
was determined with a commercial kit based on the
Bradford method (BioRad, Hemel Hempstead, UK).
Ten to twenty micrograms of protein was assayed for
cloramphenicol acetyl transferase (CAT) activity using
a xylene-based method. Briefly, total volume for each
cellular extract was adjusted to 85ml with 0.25 M
Tris –HCl (pH 7.5) and then a mixture containing
32ml 0.25 M Tris–HCl, 5ml butyril CoA (5 mg/ml)
and 3ml [14C]cloramphenicol (0.1 mCi/ml) was
added. The reaction mixture was incubated for 4 h at
37 8C and the reaction was stopped by addition of a
mixture of 2:1 2,6,10,14-tetramethylpentadecane
(Pristane, Sigma): xylene isomer (Sigma, St Louis, Mis-
souri, USA). The mixture was shaken vigorously for
30 s and spun at 14000 r.p.m. for 15 min. Two hun-
dred microlitres of the upper phase were taken and
added to 4 ml Optiphase Highsafe 2 liquid scintillation
cocktail (Perkin Elmer Life Sciences, Boston, USA).
Total counts (counts per minute, c.p.m.) were detected
using a 1214 beta liquid scintillation counter and
normalised against micrograms of protein. Luciferase
activity was determined with a commercial kit (Pro-
mega, Madison, WI, USA). b-galactosidase activity
was assayed as described elsewhere (25) by using o-p-
nitrophenil phosphate as a substrate.
Cell viability assay
Cell viability was studied using a Crystal Violet-based
staining method. Briefly, cells were plated in 60 mm
plates at a density of 1 £ 104 cells/plate. Sixteen
hours after seeding cells were serum depleted and
treated with different doses of GH during a further
4 h and subjected to different doses of radiation. Cells
536 O Madrid and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (2002) 147
www.eje.org
were allowed to grow for 10 days, fixed with glutaralde-
hyde and stained with Crystal Violet as previously
described (27). Alternatively cells were seeded at a
density of 20 £ 104 cells in 24-well dishes and stained
after 72 h of treatment.
Results
Treatment of cells with GH increases cell
survival after irradiation
Several in vitro models have been developed to study
regulation via the GH receptor (28, 29). For this
study we chose CHO-4 cells, which express rat GH
receptor cDNA, and as a control cell line, HEK293T
cells that are not responsive to GH. In order to establish
the response conditions of the two cell lines we carried
out transfection experiments using a reporter plasmid,
SPIGLE1, containing the GAS sequence from the SPI
2.1 promoter and a STAT5 binding site (30). Both
HEK293T and CHO-4 cells were transfected with
either the reporter plasmid or the empty vector. As
expected, even at high doses of GH, HEK293T cells
did not present variations in promoter-driven trans-
cription (Fig. 1). On the contrary, in CHO-4 cells,
there was a dose-dependent activation of the promoter
in response to GH at doses that have not been described
to be antagonistic (31). These results confirmed that
the two systems were suitable for our purposes. In
order to investigate the potential role of GH in radiologi-
cal protection, HEK293T and CHO-4 cells were seeded
at low density in 60 mm dishes, deprived of serum for
16 h and treated with different doses of GH for 4 h.
Cells were then subjected to irradiation and allowed
to grow for 10 days. As shown in Fig. 2, no difference
in the survival profile of HEK293T cells was observed in
either the presence or absence of GH. In contrast,
CHO-4 cells showed increased survival when they had
been exposed to GH prior to irradiation (Fig. 2). This
effect was dose dependent, indicating that it was
mediated by the biological activity of the GH receptor.
We have observed that higher doses (400 nmol/l)
were toxic for cells (data not shown); consequently
the dose range used was 50–200 nmol/l. We have
also studied the effect of GH when cells were treated
with the radiomimetic drug, bleomycin, and another
drug, vincristin, which does not affect DNA in any
way (Fig. 3). Our results showed that GH was also
able to protect CHO-4 cells from bleomycin-induced
cell death. In contrast, when cells were treated with
the microtubule interfering agent vincristin, GH was
not able to protect cells from the cytotoxic activity of
the drug. These findings suggest that the protection
induced by GH can be specific against agents that pro-
voke DNA double-strand breaks.
Treatment of cells with GH facilitates repair of
transfected DNA
Although the protective effect observed in cells treated
with GH could be due to interference by the hormone in
the response of the cells to irradiation at different levels,
the above results strongly support the hypothesis that
GH increases the activity of the DNA repair machinery.
In order to test this possibility we performed different
assays measuring reactivation of gene expression after
irradiation in the presence of GH, as an indicator of
DNA repair. CHO-4 cells were transfected with the plas-
mid pHIV-LUC, starved of serum for 16 h, treated with
GH for 4 h and then irradiated and collected at different
times. No effect of GH on basal transcription of the
pHIV-LUC reporter was detected (data not shown),
indicating that any change in the activity could be
due to repair of the damaged plasmid. As shown in
Fig. 4A, a time-dependent decrease in luciferase activity
was observed, after irradiation, in the absence of GH. In
contrast, cells pretreated with GH maintained luciferase
activity during the 24 h period, indicating that repair
Figure 1 Induction of STAT5 dependent transcription by GH in CHO-4 cells. HEK293T and CHO-4 cells were transfected with 5mg
SPIGLE1 plasmid or empty vector. After 16 h of growth in low serum medium, cells were stimulated with the indicated doses of GH,
harvested after 6 h of treatment and processed for CAT activity. Data represent mean and standard deviation of a single experiment
performed in triplicate. The experiment was performed three times in triplicate and the results were similar.
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of the transcribed strand was more active in the pre-
sence of GH. To confirm this effect of GH, additional
experiments were carried out in CHO-4 cells transfected
with pHIV-LUC reporter and exposed to different doses
of the radiomimetic drug bleomycin in the presence
or the absence of GH. As observed in Fig. 4B, bleomycin
treatment produced a time- and dose-dependent
decrease in luciferase activity. However, reporter
activity was maintained up to 40 h after the addition
of the drug when CHO-4 cells were pretreated with
GH. The effect of GH on the sustaining transcriptional
activity in the CHO-4 cells that were irradiated or trea-
ted with bleomycin, might be the result of inhibited
DNA degradation rather than increased DNA repair.
To clarify this possibility we treated the pHIV-LUC
reporter with two different radiation doses and then
transfected the irradiated DNA together with non-irra-
diated pCMV-bgal, as a control for transfection effi-
ciency. After transfection, cells were serum depleted
for 16 h, stimulated with different doses of GH and
collected 40 h after treatment. The results showed
that transcription of pHIV-LUC decreased in a
dose-dependent fashion when DNA was irradiated
(Fig. 5). When cells were transfected with irradiated
DNA (1000 rads), the recovery of transcription was
similar with the two GH doses used. However, the high-
est GH dose was more effective than the lower doses
when the radiation dose was 3000 rads. Since the
results were corrected for differences in transfection
efficiency, these experiments strongly suggest that the
action of GH on transcription reactivation was due to
repair of the damaged pHIV-LUC reporters.
Discussion
This study demonstrates that GH is radioprotective in
CHO-4 cells that express the GH receptor and the pro-
tective action of GH on radiation-induced injury is
dose dependent. A similar conclusion was obtained
Figure 2 CHO-4 and HEK293T cell survival to radiation. HEK293T and CHO cells were seeded in 60 mm dishes, treated with GH at the
indicated concentrations and irradiated at doses ranging between 0 and 5000 rads. After 10 days cell survival was estimated by Crystal
Violet stain. Data represent means and standard deviations of a single experiment performed in triplicate. The experiments were carried
out three times in triplicate and similar results were obtained.
Figure 3 CHO-4 cells survival after vincristin and bleomycin treatment. CHO cells were seeded in 24-well dishes, and 16 h later were
treated with vincristin or bleomycin at the indicated concentrations in the presence or absence of GH (200 nmol/l). After 72 h cell survival
was estimated by Crystal Violet stain. The data represent means and standard deviations from a single experiment performed in tripli-
cate. The experiments were repeated twice and similar results were obtained.
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when the radiomimetic drug, bleomycin, was used.
Bleomycin, an agent also used in cancer treatment,
has to be activated to induce direct oxidative damage
to DNA (32). The rescue from cell death by GH seems
to be selective for agents that damage DNA, since
cells treated with the microtubule disturbing agent,
vincristin, did not show any difference when they
were pretreated with GH. Goh et al. (33) reported that
GH treatment reduces the apoptosis induced by colchi-
cine in CHO-4 cells that express the GH receptor. These
authors measured apoptosis at short time intervals
after colchicine treatment. Since our experiments
measured cell survival at 10 days after radiation
exposure and 72 h after drug treatment, we believe
our data measure the fraction of survival after treat-
ment more accurately. Many actions of GH are
mediated by IGF-I, and both factors share many over-
lapping effects in both physiological and cellular
terms; IGF-I possesses antiapoptotic effects. It even
up-regulates the level of bcl-xL gene product (34), a
member of the antiapoptotic Bcl-2 family. In our
study, the survival effect observed in GH-treated CHO-
4 cells was not due to induced IGF-I secretion, since
CHO-4 cells neither synthesise nor secrete IGF-I either
when deprived of serum or after GH stimulation (35, 31).
One of the mechanisms for radioprotection involves
induction of biochemical and enzymatic pathways that
prevent radiation-induced damage and/or promote DNA
repair (36). We have found that plasmid DNA transfected
in CHO-4 cells was more actively transcribed in cells trea-
ted with GH than in non-treated cells. Transcription
activity also recovered more quickly in GH-treated cells
exposed to bleomycin. These results suggest that GH acti-
vates pathways involved in DNA repair processes.
Another explanation for our results would be that cell
death inhibition, induced by GH, could protect either plas-
mid DNA or the protein product from degradation, and
this would produce a more active transcription. However,
reporter plasmid transcription was also more active in
cells transfected with radiation-damaged DNA when
Figure 4 Reactivation of pHIV-LUC expression in CHO-4 cells after treatment with radiotherapy and bleomycin. (A) CHO-4 cells were
transfected with pHIV-LUC reporter vector. After 16 h of low serum growth cells were treated with GH at the indicated doses and
irradiated with 1000 rads. Cell lysates were prepared at the indicated times and assayed for luciferase activity. Data represent the
means of three experiments performed in duplicate. (B) CHO-4 cells were transfected with pHIV-LUC reporter vector. After 16 h of low
serum growth cells were treated with GH at the indicated doses and treated with the indicated doses of bleomycin. Cell lysates were
prepared at the indicated times and assayed for luciferase activity. Data represent the means and standard deviations from three
experiments performed in duplicate.
Figure 5 Reactivation of irradiated pHIV-LUC
expression in CHO-4 cells after treatment
with GH. pHIV-LUC plasmid was treated with
two doses of g-radiation (1000 and
3000 rads) and 2mg were cotransfected with
5mg non-irradiated pCMV-bgal plasmid in
CHO-4 cells. After 16 h of low serum growth
cells were treated with GH. Cell lysates were
prepared after 40 h and assayed for
luciferase activity and b-galactosidase.
Efficiency of transfection was corrected as
indicated in Materials and methods. Data
represent means and standard deviations
from three experiments performed in
duplicate.
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they were pre-treated with GH. Since the cells them-
selves were not exposed to radiation, the observed effects
cannot be a consequence of apoptotic protection and
suggest that DNA repair has been activated. This finding
is also consistent with a recent study in rat liver (37)
showing that GH induces the expression of several
genes implicated in the control of DNA damage and in
the response of cells to stress. Namely, GADD45, which
inhibits mitotic growth (38), and APEN, which is both
a DNA repair enzyme (39) and an activator of several
transcription factors (40). Thus, GH may have a role
in defending against cell stress and DNA damage. In
this line, the results shown here may also explain an
effect reported by our group in rats which were exposed
to abdominal g-radiation and whose survival was
increased by 50% if the animals had been treated with
human GH (24). The increase in survival was associated
with reduced bacterial translocation, speedier increases
in mucosal thickness and proliferative index and a
decrease in apoptosis, suggesting that giving GH to irra-
diated rats promoted the adaptive process of the intestine
against acute radiation-related negative effects.
Interaction of GH with its receptor induces the
activation of signalling cascades including the JAK2
tyrosine kinase (41), MAPK (42, 31), activation of
insulin receptor substrate (IRS)-1 and IRS-2 (43, 44),
Phosphatidylinositol 3-kinase (45), Src homologous
and collagen-like protein, Grb2 (46), Protein kinase C
and phospholipase A2 (16) among others. Some of
these pathways, particularly those driven by JAK2
and MAPK, can activate transcription mediated by
STAT3 and STAT5 as well as SRF and c-fos (47, 30,
48) and probably activate expression of genes like
GADD45 and APEN, which are involved in radiation-
induced DNA repair. Alternatively, other signal trans-
duction pathways activated by GH could be at the
translation level and would activate the assemblage of
DNA repair complexes. These possibilities are the
subjects of ongoing research by our group.
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